These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 19176464)
1. Trial offers early test case for personalized medicine. Garber K J Natl Cancer Inst; 2009 Feb; 101(3):136-8. PubMed ID: 19176464 [No Abstract] [Full Text] [Related]
2. Trastuzumab--mechanism of action and use in clinical practice. Hudis CA N Engl J Med; 2007 Jul; 357(1):39-51. PubMed ID: 17611206 [No Abstract] [Full Text] [Related]
3. Neoadjuvant trials could speed up drug approvals. Peres J J Natl Cancer Inst; 2014 Mar; 106(3):dju072. PubMed ID: 24610911 [No Abstract] [Full Text] [Related]
4. The FUTURE of ErbB-1 and ErbB-2 pathway inhibition in breast cancer: targeting multiple receptors. Slamon DJ Oncologist; 2004; 9 Suppl 3():1-3. PubMed ID: 15163840 [No Abstract] [Full Text] [Related]
5. Experts debate value of HER2 testing methods. Nelson NJ J Natl Cancer Inst; 2000 Feb; 92(4):292-4. PubMed ID: 10675369 [No Abstract] [Full Text] [Related]
6. [The use of targeted therapies in oncology and their impact in the design of clinical trials: epidermal growth factor receptors 1 and 2 as a paradigm]. Dalmases A; Rojo F; Rovira A; Albanell J Med Clin (Barc); 2013 Aug; 141(4):176-80. PubMed ID: 23809407 [No Abstract] [Full Text] [Related]
7. Biotech firm faces challenges from FDA, falling stock prices. Reynolds T J Natl Cancer Inst; 2002 Mar; 94(5):326-8. PubMed ID: 11880468 [No Abstract] [Full Text] [Related]
8. Can cancer clinical trials be fixed? Allison M Nat Biotechnol; 2011 Jan; 29(1):13-5. PubMed ID: 21221090 [No Abstract] [Full Text] [Related]
9. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Berns K; Horlings HM; Hennessy BT; Madiredjo M; Hijmans EM; Beelen K; Linn SC; Gonzalez-Angulo AM; Stemke-Hale K; Hauptmann M; Beijersbergen RL; Mills GB; van de Vijver MJ; Bernards R Cancer Cell; 2007 Oct; 12(4):395-402. PubMed ID: 17936563 [TBL] [Abstract][Full Text] [Related]
10. ErbB/HER receptor family in breast cancer--the more we search the more we learn. Karamouzis MV; Konstantinopoulos PA; Papavassiliou AG Ann Oncol; 2008 May; 19(5):1020-1. PubMed ID: 18356136 [No Abstract] [Full Text] [Related]
11. PI3 kinase activation and response to Trastuzumab Therapy: what's neu with herceptin resistance? Park BH; Davidson NE Cancer Cell; 2007 Oct; 12(4):297-9. PubMed ID: 17936554 [TBL] [Abstract][Full Text] [Related]
12. Targeted cancer therapies attempt to hit the bull's-eye. Miller M J Natl Cancer Inst; 2000 Dec; 92(23):1878-9. PubMed ID: 11106678 [No Abstract] [Full Text] [Related]
13. Researchers may use cancer cell lines to identify target populations prior to clinical trials. Tuma RS J Natl Cancer Inst; 2006 Jun; 98(12):810-1. PubMed ID: 16788154 [No Abstract] [Full Text] [Related]
14. Melanoma drug wins US approval. Ledford H Nature; 2011 Mar; 471(7340):561. PubMed ID: 21455150 [No Abstract] [Full Text] [Related]
15. Programmed death protein 1 inhibitors making inroads in multiple cancers. Brower V J Natl Cancer Inst; 2015 May; 107(5):. PubMed ID: 25957444 [No Abstract] [Full Text] [Related]
17. Response of metastatic breast cancer to trastuzumab? Barnes DM; Miles DW Lancet; 2000 Jan; 355(9199):160-1. PubMed ID: 10675110 [No Abstract] [Full Text] [Related]
18. Therapeutic monoclonal antibodies for the ErbB family of receptor tyrosine kinases. Zhang H; Richter M; Greene MI Cancer Biol Ther; 2003; 2(4 Suppl 1):S122-6. PubMed ID: 14508089 [TBL] [Abstract][Full Text] [Related]